These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2272043)
1. High-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia--preliminary clinical and pharmacological data of a randomized comparison. Hiddemann W; Schleyer E; Uhrmeister C; Aul CH; Maschmeyer G; Heinecke A; Büchner T Cancer Treat Rev; 1990 Sep; 17(2-3):279-85. PubMed ID: 2272043 [TBL] [Abstract][Full Text] [Related]
2. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Hiddemann W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Becker K; Balleisen L; Lathan B Leuk Lymphoma; 1993; 10 Suppl():133-7. PubMed ID: 8481662 [TBL] [Abstract][Full Text] [Related]
3. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189 [TBL] [Abstract][Full Text] [Related]
4. Age related randomized comparison of sequentially applied high-dose versus intermediate dose cytosine arabinoside in combination with mitoxantrone (S-HAM) in the treatment of relapsed and refractory acute myeloid leukemia: study design and preliminary results. Hiddemann W; Aul C; Maschmeyer G; Lathan B; Köppler H; Hoffmann R; Grüneisen T; Donhuijsen-Ant R; Ludwig WD; Balleisen L Onkologie; 1989 Feb; 12(1):4-6. PubMed ID: 2654790 [TBL] [Abstract][Full Text] [Related]
5. Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. Hiddemann W; Schleyer E; Unterhalt M; Zühlsdorf M; Rolf C; Reuter C; Kewer U; Uhrmeister C; Wörmann B; Büchner T Leukemia; 1992 Dec; 6(12):1273-80. PubMed ID: 1453772 [TBL] [Abstract][Full Text] [Related]
6. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Kern W; Schleyer E; Unterhalt M; Wörmann B; Büchner T; Hiddemann W Cancer; 1997 Jan; 79(1):59-68. PubMed ID: 8988727 [TBL] [Abstract][Full Text] [Related]
7. High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemias. Hiddemann W; Büchner T; Essink M; Koch O; Stenzinger W; van de Loo J Onkologie; 1988 Feb; 11(1):10-2. PubMed ID: 3283619 [TBL] [Abstract][Full Text] [Related]
8. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of cytosine arabinoside between leukemic blasts and normal mononuclear blood cells. Hiddemann W; Schleyer E; Unterhalt M; Kern W; Büchner T Ther Drug Monit; 1996 Aug; 18(4):341-9. PubMed ID: 8857548 [TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125 [TBL] [Abstract][Full Text] [Related]
10. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685 [TBL] [Abstract][Full Text] [Related]
11. Oral cytarabine ocfosfate in acute myeloid leukemia and non-Hodgkin's lymphoma--phase I/II studies and pharmacokinetics. Braess J; Freund M; Hanauske A; Heil G; Kaufmann C; Kern W; Schüssler M; Hiddemann W; Schleyer E Leukemia; 1998 Oct; 12(10):1618-26. PubMed ID: 9766508 [TBL] [Abstract][Full Text] [Related]
12. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638 [TBL] [Abstract][Full Text] [Related]
13. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A; Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637 [TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative Group. Kern W; Aul C; Maschmeyer G; Kuse R; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W Ann Hematol; 1998 Sep; 77(3):115-22. PubMed ID: 9797080 [TBL] [Abstract][Full Text] [Related]
15. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group. Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490 [TBL] [Abstract][Full Text] [Related]
16. Proposal for the classification of relapsed and refractory acute myeloid leukemias as the basis for an age-adjusted randomized comparison of sequentially applied high-dose versus intermediate-dose cytosine arabinoside in combination with mitoxantrone (S-HAM). Hiddemann W; Aul HC; Maschmeyer G; Urbanitz D; Lathan B; Reichle A; Köppler H; Donhuijsen-Ant R; Ludwig WD; Grüneisen T Haematol Blood Transfus; 1990; 33():604-10. PubMed ID: 2182450 [No Abstract] [Full Text] [Related]
17. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302 [TBL] [Abstract][Full Text] [Related]
18. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study. Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729 [TBL] [Abstract][Full Text] [Related]
19. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]